secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001104659-24-075709
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma nominates first in vivo CAR-M candidate under Moderna collab; $2M milestone triggered
--------------------------------------------------------------------------------

- Development candidate targets Glypican-3 for solid tumors, including hepatocellular carcinoma (HCC).
- Nomination triggers a $2M milestone payment to Carisma from Moderna.
- Candidate uses Carisma's CAR-M expertise and Moderna's mRNA/LNP platform for in vivo cell therapy.
- Moderna leads development and commercialization; four undisclosed oncology targets also nominated.
- Pre-clinical data showed successful in vivo creation of CAR-M redirecting myeloid cells against cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924075709/0001104659-24-075709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924075709/tm2418383d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-075709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer